Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 9,900 shares, a growth of 54.7% from the May 31st total of 6,400 shares. Based on an average daily trading volume, of 32,700 shares, the short-interest ratio is presently 0.3 days. Approximately 0.5% of the company’s shares are sold short.

Tenax Therapeutics Trading Up 1.2 %

Shares of NASDAQ TENX traded up $0.03 during mid-day trading on Friday, hitting $3.01. 4,161 shares of the stock traded hands, compared to its average volume of 21,288. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $61.20. The stock has a fifty day moving average price of $3.45 and a 200-day moving average price of $7.30.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Research analysts forecast that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Tenax Therapeutics in a research note on Sunday. They set a “sell” rating on the stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.